CD274 and neoplasm: Thus, the therapeutic success of the Folfox/Anti-PD-1 combination therapy is linked to the Folfox-driven induction of an anticancer immune response that drives tumor adaptive immune resistance through the PD-1/PD-L1 pathway (75).